Headquartered in New York, NY Fiscal year ends December NASDAQ: PGNY progyny.com
Progyny (Nasdaq: PGNY) provides women's health and family building benefit solutions to employers, health plans, and benefit purchasers. The company operates two primary service lines: fertility benefit services, which include concierge support, coaching, education, digital tools, and access to a premier network of fertility and women's health specialists; and pharmacy benefit services, which manage the pharmaceutical component of fertility treatments. Progyny's platform is designed to drive optimal clinical outcomes while reducing healthcare costs for employers. As of Q2 2026, the company served 604 fertility and family building clients covering approximately 7.2 million average eligible members. Revenue is generated through per-treatment and per-member fees from employer clients, with the business exhibiting seasonality tied to member engagement patterns and an annual selling season for new client launches. Updated
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen…
Progyny (Nasdaq: PGNY) provides women's health and family building benefit solutions to employers, health plans, and benefit purchasers.
24/7 Wall St.'s 12-month price target for PGNY is $35.83, rated Buy. The Wall Street consensus target is $34.42. PGNY price prediction →
